Carregant...
4CPS-142 Analysis of prescribing and clinical outcomes of vedolizumab treatment in a university care hospital
BACKGROUND: Vedolizumab became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). The Spanish Drug Agency provided a Therapeutic Positioning Report about the clinical recommendation in the use of vedolizumab and its public funds. PURPOSE:...
Guardat en:
| Publicat a: | Eur J Hosp Pharm |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Group
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535458/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.233 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|